Rodent models lacking IL-6 have shown decreased inflammation and pulmonary vascular phenotype of PAH, while IL-6 antagonists have abated the development of pulmonary vascular remodeling and PH (PAH is still called PH in animal models). The gene discussed is IL6; the disease is pulmonary arterial hypertension.